Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2007; 97(05): 866-868
DOI: 10.1160/TH06-04-0195
DOI: 10.1160/TH06-04-0195
Letters to the Editor
Any effect of CYP2C9 variants on warfarin clearance in Chinese patients?
Authors
Financial support: The study was supported by a Direct Grant for Research (project code: 2041154) from The Chinese University of Hong Kong.
Further Information
Publication History
Received
09 April 2006
Accepted after resubmission
21 February 2007
Publication Date:
24 November 2017 (online)
-
References
- 1 Zhao F, Loke C, Rankin SC. et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-219.
- 2 Yuan HY, Chen JJ, Lee MTM. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
- 3 Chern HD, Ueng TH, Fu YP. et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 2006; 367: 108-113.
- 4 You JHS, Chan FWH, Wong RSM. et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. Br J Clin Pharmacol 2005; 59: 582-587.
- 5 Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
- 6 Chan E, McLachlan A, O’Reilly R. et al. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-294.
- 7 Haber LT, Maier A, Gentry PR. et al. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg Toxicol Pharmacol 2002; 35: 177-197.
- 8 Veenstra DL, You JHS, Rieder MJ. et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-691.
- 9 Naidong W, Ring PR, Midtlien C. et al. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. J Pharm Biomed Anal 2001; 25: 219-226.
- 10 Takahashi H, Kashima T, Nomizo Y. et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
- 11 Takahashi H, Wilkinson G, Caraco Y. et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-263.
- 12 Takahashi H, Ieiri I, Wilkinson GR. et al. 5’-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055-3057.
- 13 Takahashi H, Wilkinson GR, Nutescu EA. et al. Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
- 14 Sconce EA, Khan TI, Wynne HA. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
- 15 Kamali F, Khan TI, King BP. et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-212.
- 16 Wynne H, Cope L, Kelly P. et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Pharmacol 1995; 40: 203-207.
- 17 Scordo MG, Pengo V, Spina E. et al. Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.